PMID- 14533279
OWN - NLM
STAT- MEDLINE
DCOM- 20031029
LR  - 20161020
IS  - 1122-0643 (Print)
IS  - 1122-0643 (Linking)
VI  - 59
IP  - 1
DP  - 2003 Jan-Mar
TI  - Anti-IgE monoclonal antibody: a new approach to the treatment of allergic 
      respiratory diseases.
PG  - 25-9
AB  - The immunoglobulin E (IgE) antibody plays a central role in the allergic immune 
      responses. The ability to reduce circulating IgE with a humanized monoclonal 
      antibody (omalizumab) represents a new therapeutic approach for the treatment of 
      IgE-mediated allergic diseases. The use of an anti-IgE antibody in the treatment 
      of asthma was first suggested in preliminary studies in which omalizumab 
      demonstrated efficacy in attenuating both the early- and late-phase bronchial 
      responses to inhaled aeroallergens. Therapy with omalizumab has demonstrated both 
      a significant beneficial effect on a number of measures and a favorable safety 
      profile. It reduces the frequency of asthma exacerbations and the need for 
      inhaled corticosteroids (ICSs), and improves asthma symptoms, lung function, and 
      quality of life. The anti-IgE approach to asthma treatment has several potential 
      advantages, such as the treatment of other concomitant atopic diseases (allergic 
      conjunctivitis and rhinitis, atopic dermatitis, and food allergy) regardless of 
      atopiC of allergic sensitization.
FAU - D'Amato, G
AU  - D'Amato G
AD  - Division of Respiratory and Allergic Diseases, High Speciality Hospital A. 
      Cardarelli, Naples, Italy.
FAU - Oldani, V
AU  - Oldani V
FAU - Donner, C F
AU  - Donner CF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Monaldi Arch Chest Dis
JT  - Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
JID - 9307314
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Antibodies, Anti-Idiotypic/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Humans
MH  - Hypersensitivity/*drug therapy
MH  - Immunoglobulin E/*immunology
MH  - Omalizumab
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Tract Diseases/*drug therapy
RF  - 15
EDAT- 2003/10/10 05:00
MHDA- 2003/10/30 05:00
CRDT- 2003/10/10 05:00
PHST- 2003/10/10 05:00 [pubmed]
PHST- 2003/10/30 05:00 [medline]
PHST- 2003/10/10 05:00 [entrez]
PST - ppublish
SO  - Monaldi Arch Chest Dis. 2003 Jan-Mar;59(1):25-9.